SCHEMBL5176049

SCHEMBL5176049

COC(=O)CCc1cnc(N2CC[C@H](OC(C)C(=O)Cc3cc(Cl)c(NC(=O)c4cn(C)c5ccccc45)cc3Cl)C2)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 9/20 0.48
ITGA4 P13612 9/20 0.48
KDM1A O60341 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
S1PR2 O95136 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TP53 P04637 2/20 0.32
LMNA P02545 1/20 0.32
HDAC6 Q9UBN7 2/20 0.32
HTR4 Q13639 1/20 0.32
PIK3CD O00329 1/20 0.31
HDAC3 O15379 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163502 0.95 ITGB1 (0.50) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5176268 0.95 ITGB1 (0.49) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5159935 0.90 ITGA4 (0.52) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5176045 0.88 ITGB1 (0.45) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5161126 0.88 ITGB1 (0.45) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5158245 0.84 ITGB1 (0.47) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5414832 0.83 ITGB1 (0.51) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5163411 0.83 ITGB1 (0.46) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5176265 0.83 ITGB1 (0.47) ITGB1ITGA4KDM1AMEN1KMT2A
SCHEMBL5158313 0.79 ITGB1 (0.49) ITGB1ITGA4KDM1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232601-A1 Vla-4 Inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-10-04 US disclosed
EP-1757602-A1 VLA-4 INHIBITOR DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232601-A1 Vla-4 Inhibitor VCAM1, ITGB4, ITGA4 ITGB1 9/4885ITGA4 3/4885KDM1A 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.